ZINFORO® may be associated with early clinical response at Day 31
In a retrospective integrated subgroup analysis of CANVAS 1 and CANVAS 2, ZINFORO® was associated with a trend towards early clinical response* when compared to vancomycin + aztreonam at Day 3 (P=0.018)1,†:
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
This analysis includes the following potential limitations1:
Evaluation of an end point that was not pre-specified in the original CANVAS 1 and CANVAS 2 study designs
Data collection that was not optimised for this outcome measure
Lack of a pre-specified hypothesis with the corresponding power calculations for this end point1
Greater improvement on Day 3 was seen regardless of1:
Age
Renal function status
Presence of fever
Bacteraemia
Prior antibiotic use
Infection type
*ZINFORO® was associated with an early clinical response defined by the cessation of lesion spread and the absence of fever.1
†Superiority cannot be concluded based on this retrospective integrated analysis because this was not a pre-planned analysis nor was superiority seen in each individual study.
CANVAS, CeftAroliNe fosamil versus Vancomycin in Skin and skin structure infection; cSSTI, complicated skin and soft tissue infection; MRSA, methicillin-resistant Staphylococcus aureus.
Reference:
Clinical & scientific data
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.